A phase 1a/b, multi-regional, first-in-human study of CS5001, a novel anti-ROR1 ADC, in patients with advanced solid tumors and lymphomas.
Wednesday, June 19, 2024
Dr. Minal Barve
Click the above link to view the abstract.
![ASCO 2024 Poster for Trial 22-09](https://marycrowley.org/wp-content/uploads/2024/06/Poster-10.jpg)
ASCO 2024 Poster for Trial 22-09